Search

The combination of taselisib and fulvestrant has shown to slow the growth of cancer in post-menopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2) negative, PIK3CA-mutant, inoperable, locally advanced or metastatic breast cancer. Researchers from Memorial Sloan Kettering Cancer Center (MSK) presented this data, from the SANDPIPER trial, in a press conference at the annual meeting of the American Society of Clinical Oncology. This combination of a mutant-selective PI3K inhibitor and a selective estrogen receptor degrader halted the growth of advanced breast cancer for two months longer than hormone therapy alone and decreased the chance of cancer worsening by 30 percent.

… Saturday, June 2, 2018 The combination of taselisib and fulvestrant has shown to slow the growth of cancer in post-menopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2) negative, PIK3CA-mutant, inoperable, locally advanced or metastatic breast cancer.

In partnership with the Nassau County Department of Health, MSK Nassau staff equitably distributed COVID-19 vaccinations to hundreds of residents.

… Friday, April 23, 2021 Nassau County resident receives literature from MSK nurse Nassau County resident Farrah Mozawalla receives literature from MSK nurse Curt Haase prior to receiving her second dose of the COVID-19 vaccine. MSK nurse Curt Haase administers the vaccine MSK nurse Curt Haase administers

Learn what to do if you find a lump in your breast.

… Wednesday, May 29, 2024 You might know  how to check yourself for breast lumps , but do you know what to do if you find one? Janice Shen, MD , a breast medical oncologist at Memorial Sloan Kettering Cancer Center (MSK) Commack offers these recommendations. First, don’t panic if you find a lump or change

A new health policy report which will be published in the New England Journal of Medicine suggests that the swift and dramatic rise in cancer-drug spending is due to laws that keep Medicare from managing the use or price of cancer drugs. These laws limit Medicare's actions in cancer far more than they are limited in other areas of healthcare.

… Tuesday, January 27, 2009 A new health policy report suggests that the swift and dramatic rise in cancer-drug spending is due to laws that keep Medicare from managing the use or price of cancer drugs. These laws limit Medicare’s actions in cancer far more than they are limited in other areas of healthcare

… Friday, September 5, 2025 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments:  Matthew Bott Joins the Lung Cancer Research Foundation Scientific Advisory Board Matthew Bott Matthew Bott, MD , thoracic surgeon, has  joined the Lung Cancer Research Foundation

Learn about the journey of Cornelius Taabazuing, a rising young scientist who recently won the Tri-Institute Breakout Award for Young Investigators at the Sloan Kettering Institute.

… Tuesday, May 25, 2021 At this year’s Convocation, which is the highlight of Memorial Sloan Kettering’s academic efforts, Sloan Kettering Institute postdoctoral fellow Cornelius Taabazuing was honored with a prestigious award — the 2021 Tri-Institutional (Tri-I) Breakout Award for Junior Investigators

Four MSK researchers out of 15 winners nationwide were named recipients of the prestigious award. They will each receive a grant of up to $600,000 per year for seven years to support their research in cancer.

… Thursday, October 29, 2020 Four distinguished researchers at Memorial Sloan Kettering (MSK), Joan Massagué, PhD ; Maria Jasin, PhD ; David A. Scheinberg, MD, PhD ; and Hans-Guido Wendel, MD , were named recipients of the National Cancer Institute’s (NCI) 2020 Outstanding Investigator Award (OIA). As

Researchers have redesigned CAR T cells in hopes of improving immunotherapy treatment for multiple myeloma.

… Thursday, March 28, 2019 Summary CAR T cell therapy for multiple myeloma has targeted a protein called BCMA. However, many people treated with this immunotherapy have had their cancer return. Researchers have developed an additional class of CAR T cells that target a protein called GPRC5D. This might

Tomya Watt, Chief Diversity Officer and Vice President of Talent Acquisition and Mobility, was selected to receive the 2022 Moves Mentor Award from ’Moves‘ Magazine.

… Friday, May 20, 2022 Tomya Watt , Chief Diversity Officer and Vice President of Talent Acquisition and Mobility, was selected to receive the 2022 Moves Mentor Award from Moves  magazine. The award celebrates female leaders, the role they play in shaping the next generation, and the energy, expertise,

… Monday, March 3, 2025 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments: Vinod Balachandran Awarded the Marcus Foundation Medical Research Award Vinod Balachandran, MD Vinod Balachandran, MD  surgeon-scientist and Director of the Olayan Center for Cancer